comparemela.com
Home
Live Updates
FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC : comparemela.com
FDA Panel Rejects Broad Olaparib Indication in Metastatic CRPC
ODAC votes that olaparib-abiraterone combination should be restricted to <em>BRCA</em>-positive subset
Related Keywords
California ,
United States ,
North Carolina ,
Columbia University ,
New York ,
Colorado ,
Massachusetts ,
Mike Bassett ,
Chana Weinstock ,
Daniel George ,
Los Angeles ,
Richard Pazdur ,
Neil Vasan ,
Jorge Nieva ,
Astrazeneca Laurence Toms ,
Duke Cancer Institute In Durham ,
Columbia University Medical Center ,
Oncology Center ,
Office Of Oncologic Diseases ,
University Of Colorado Cancer Center ,
Astrazeneca ,
Oncologic Drugs Advisory Committee ,
Christopher Lieu ,
Colorado Cancer Center ,
New York City ,
Oncologic Diseases ,
Southern California ,
Keck School ,
Laurence Toms ,
Duke Cancer Institute ,
comparemela.com © 2020. All Rights Reserved.